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Does combining aspirin and
warfarin decrease the risk of
stroke for patients with
nonvalvular atrial fibrillation?
■ EVIDENCE-BASED ANSWER
Adjusted-dose warfarin (international normal-
ized ratio [INR]=2.0–3.0) remains the most 
efficacious antithrombotic regimen for the 
primary and secondary prevention of cardio-
embolic stroke in high-risk patients with 
nonvalvular atrial fibrillation (NVAF) (strength
of recommendation [SOR]: A, based on random-
ized controlled trials). 
Aspirin therapy at a dose of 75 to 325 mg
reduces the risk of stroke to a lesser degree and
may be useful for low-risk patients with NVAF
or patients at high risk for bleeding (SOR: A,
based on randomized controlled trials). 
Combination therapy with low, fixed-dose
warfarin (1–2 mg) and aspirin has not been
shown to be superior to aspirin therapy alone.
Moreover, this combination appears to be inferi-
or to adjusted-dose warfarin (SOR: A, based 
on randomized controlled trials). To date, no
clinical trials have investigated the efficacy 
and safety of combining adjusted-dose warfarin
and aspirin for the prevention of stroke from
NVAF. 
■ EVIDENCE SUMMARY
Thromboprophylaxis with warfarin for patients
with NVAF has been studied in 5 major clinical
trials.1–5 Pooled analysis with more than 2900
patients revealed an annual stroke risk of 4.5%
for control patients and 1.4% for patients
receiving adjusted-dose warfarin (number need-
ed to treat [NNT] for 1 year=32).6 Studies com-
paring aspirin with placebo for treatment of
NVAF are less robust and have heterogeneous
results. Combined data from the Atrial
Fibrillation Aspirin Anticoagulation Study
(AFASAK-1),1 the European Atrial Fibrillation
Trial,7 and the Stroke Prevention in Atrial
Fibrillation (SPAF) I studies2 revealed a small
but statistically significant reduction in stroke
rates (relative risk reduction [RRR]=21%;
8.1% vs 6.3% annual stroke rate; NNT=55),
with no increase in major bleeding risk.8
The SPAF III investigators further com-
pared adjusted-dose warfarin with low-intensi-
ty, fixed-dose warfarin plus aspirin in high-risk
patients with NVAF.9 An interim analysis at 1.1
years revealed superiority in the reduction of
ischemic strokes and systemic embolisms with
adjusted-dose warfarin (7.9% vs 1.9% per year,
respectively; NNT=16), which led to the trial’s
termination. Rates of major hemorrhage did
not differ between treatment groups (2.4% per
year with combination vs 2.1% per year with
warfarin). 
Two similar studies published in 1998 were
terminated early, in light of the SPAF III
results. The Second Copenhagen Atrial
Fibrillation, Aspirin, and Anticoagulation
Study10 (AFASAK-2) completed 3 of the sched-
uled 6 years; it compared warfarin 1.25 mg/d,
warfarin 1.25 mg/d plus aspirin 300 mg,
aspirin 300 mg alone, and adjusted-dose war-
farin (INR=2.0–3.0) to treat NVAF for patients
with a median age of 74 years (range, 44–89).
The cumulative stroke event rate after 1 year
was 5.8% on fixed-dose warfarin, 7.2% on com-
bination, 3.6% on aspirin, and 2.8% on adjust-
ed-dose warfarin. The researchers concluded
that while the difference was not statistically
significant, adjusted-dose warfarin seemed
superior to other treatments after 1 year.
In a similar fashion, Pengo et al11 random-
ized patients with NVAF aged >60 years to
fixed-dose (1.25 mg/d) or adjusted-dose war-
farin (INR=2.0–3.0) to evaluate ischemic
stroke rates and major bleeding. This trial
enrolled 303 patients who were followed up for
14.5 months before discontinuation of the trial.
The rate of ischemic stroke was significantly
higher in the fixed-dose warfarin group com-
pared with the adjusted warfarin group (3.7%
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vs 0% per year; NNT=27). Major bleeds were
more frequent in the adjusted warfarin group
(2.6% vs 1% per year, number needed to
harm=63). While the combined primary end-
point did not show a significant benefit for
adjusted-dose warfarin, this study suggests that
fixed-dose warfarin does not protect against
ischemic stroke in NVAF patients. 
The intensity of warfarin therapy and stroke
severity has recently been studied for patients
with NVAF.12 A subtherapeutic INR (<2.0) on 
the day of admission was independently associ-
ated with severe stroke (odds ratio=1.9; 95%
confidence interval [CI], 1.1–3.4), and risk of
death at 30 days (hazard ratio, 3.4; 95% CI,
1.1–10.1) compared with an INR of 2.0 or
greater. Furthermore, an admission INR of
1.5–1.9 had a similar mortality rate (18%) as an
INR of <1.5 (15%), and for those patients on
aspirin (15%). 
These findings further support the impor-
tance of achieving therapeutic INR goals for
patients with NVAF.
■ RECOMMENDATIONS FROM OTHERS
The American Heart Association, the American
College of Cardiology,13 and the American
College of Chest Physicians (ACCP)14 recom-
mend adjusted-dose warfarin for nonvalvular
atrial fibrillation patients at high risk for
ischemic stroke. Risk stratification is a key
component in order to maximize efficacy while
minimizing bleeding risk. 
The Table summarizes the ACCP guidelines for
prevention of ischemic stroke based on patient
risk factors. 
Sandy L. Robertson, PharmD, Cabarrus Family
Medicine Residency Program, Northeast Medical Center,
Concord, NC; Jill Byerly Mayer, MLIS, AHIP, Health
Sciences Library, University of North Carolina–Chapel Hill
Appli
ACCP Stroke Prevention Guidelines 2001
Atrial fibrillation 
stroke profile Risk factors Treatment guidelines
High risk One or more of the following: Warfarin (INR=2.5; range, 2–3)
Age 75 years
History of hypertension
Cerebrovascular accident/
transient ischemic attack
Arterial thromboembolism
Poor left ventricular systolic 
dysfunction (ejection fraction <40%)
Rheumatic mitral valve disease 
or prosthetic heart valve
2 or more moderate risk factors
Moderate risk No high risk factors and 1 of the following: Warfarin (INR=2.5, range, 2–3) or
Age 65–74 years Aspirin 325 mg/d
Diabetes
Coronary artery disease
Low risk No high or moderate risk factors and: Aspirin 325 mg/d
Age <65 years
INR, international normalized ratio
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■ CLINICAL COMMENTARY:
When warfarin is started, 
aspirin should be stopped
The lack of evidence to support the combined
use of aspirin and warfarin creates an excellent
opportunity to remove an unnecessary drug
from a patient’s medication list. Patients who
were taking aspirin for thrombosis prophylaxis
occasionally develop atrial fibrillation. Many
patients who take aspirin for prophylaxis do so
because they are already at moderate to high
risk for embolic stroke. The onset of atrial fib-
rillation in these patients appropriately leads to
the initiation of warfarin. At the time of war-
farin initiation, the aspirin should be stopped.
By stopping the aspirin at the initiation of the
warfarin, one can reduce the number of med-
ications that the patient must take, avoid the
interactions of aspirin and warfarin, and elimi-
nate the side the effects of the aspirin.
Rick Guthmann, MD, Illinois Masonic Family Practice
Residency, University of Illinois at Chicago
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Do statins reduce 
the risk of stroke?
■ EVIDENCE-BASED ANSWER
HMG Co-A reductase inhibitors (statins) are effec-
tive for primary prevention of ischemic stroke in
people who have a history of occlusive artery dis-
ease, coronary artery disease, or diabetes without
history of cerebrovascular disease (strength of
recommendation [SOR]: A, based on 1 random-
ized controlled trial [RCT]).
Statins reduce the risk of ischemic stroke in
hypertensive patients with multiple cardiovascu-
lar risk factors and nonfasting total cholesterol
<250 mg/dL (SOR: A, based on RCT). Statins also
reduce the risk of ischemic stroke for patients
with coronary disease or equivalents (such as dia-
betes or peripheral artery disease), including
patients who have a normal fasting lipid profile
(SOR: A, based on RCT). For patients with
ischemic stroke who have coronary disease,
statins prevent recurrent ischemic stroke; evi-
dence is conflicting about whether this benefit is
proportional to initial cholesterol levels (SOR: A,
systematic review). Statins do not prevent hemor-
rhagic stroke (SOR: A, based on RCTs).
